Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals Inc. (LXRX) delivers innovative genomic-driven therapies for chronic diseases through its proprietary drug discovery platform. This page provides centralized access to official press releases, clinical trial updates, and strategic developments from the biopharmaceutical innovator.
Investors and industry observers will find timely updates on key initiatives including neuropathic pain treatment LX9211, diabetes therapies, and cardiovascular research. The resource aggregates regulatory milestones, partnership announcements, and scientific presentations while maintaining strict compliance with financial disclosure standards.
All content undergoes verification against primary sources to ensure accuracy. Users can monitor developments across Lexicon's pipeline – from preclinical research to commercialized products like INPEFA® – through curated news streams free of promotional language.
Bookmark this page for efficient tracking of LXRX's progress in advancing non-opioid pain management solutions and targeted metabolic therapies. Regular updates provide critical insights into the company's position within the evolving biopharmaceutical landscape.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced publication of preclinical data on ACSL5 in the Journal of the Endocrine Society on Dec 10, 2025, reinforcing the rationale for its oral ACSL5 inhibitor LX9851. Animal studies showed ACSL5 knockout mice and mice given potent oral ACSL5 inhibitors had lower body weight and body fat, reduced triglycerides, total cholesterol and blood glucose, and preserved lean mass versus controls.
Mechanistic work linked effects to activation of the ileal brake, which delayed gastric emptying and reduced food intake. Lexicon holds an exclusive worldwide license for LX9851 with Novo Nordisk (March 2025).
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present clinical data on sotagliflozin's effect on adipose tissue distribution in non-diabetic patients with HFpEF at CVCT 2025.
The data derive from SOTA-P-CARDIA, a prospective, randomized, double-blind, placebo-controlled trial conducted by Mount Sinai Medical Center. The presentation is scheduled for Monday, December 8, 2025 at 10:30 a.m. ET and will be delivered by Juan Jose Badimon, Ph.D., at the 22nd Global Cardio Vascular Clinical Trialists Forum (December 8-10, 2025) at the Mayflower Hotel, Washington, D.C.
Lexicon highlighted this dataset alongside recent cardiac remodeling and MACE data as additional evidence of sotagliflozin's differentiated effects versus SGLT2 inhibitors.
Lexicon Pharmaceuticals (Nasdaq: LXRX) said management will participate in two investor conferences in early December 2025: a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 9:00 AM ET and a presentation at the Evercore 8th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:10 AM ET.
Live events and replays will be available on the company’s Events page at https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18, 2025 at 5:00 p.m. GMT (12:00 p.m. EST).
The live event and replay will be available via the company’s Events page on its investor website: https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported new clinical data presented at AHA 2025 showing sotagliflozin produced statistically significant improvements in cardiac structure, diastolic function, six-minute walk distance and KCCQ scores in patients with preserved ejection fraction heart failure (HFpEF) without diabetes.
The prospective, randomized, double-blind, placebo-controlled SOTA P CARDIA trial enrolled 88 racially diverse participants (70% female) treated for six months. Peak VO2 improved but did not reach statistical significance. The company highlighted these results as the first demonstration of clinical benefit for HFpEF patients without diabetes.
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q3 2025 results and R&D updates on Nov 6, 2025. Key financials: Q3 revenue $14.2M (vs $1.8M YoY) driven by a $45M upfront from Novo Nordisk and $1.0M INPEFA sales; net loss $12.8M or $0.04/share (vs $64.8M). Cash and investments were $145.0M at Sept 30, 2025.
Pipeline highlights: pilavapadin (LX9211) Phase 2b data support 10 mg dose and an FDA end-of-Phase 2 meeting in Q4 2025; LX9851 IND-enabling studies completed and licensed to Novo Nordisk (upfront $45M; up to $1B total; potential near-term $30M milestone); SONATA-HCM Phase 3 site initiation complete with 130 sites and enrollment target 500; Zynquista resubmission data submitted to FDA.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that data from three sotagliflozin studies will be presented at the Hypertrophic Cardiomyopathy Society sessions and the American Heart Association Scientific Sessions 2025 in New Orleans on November 7–10, 2025.
Presentations include an oral talk on sotagliflozin reversing adverse cardiac remodeling in HCM mice (Nov 7, 3:00–3:10 PM CT), a Late‑breaking oral trial in HFpEF patients without diabetes (Nov 8, 2:20–2:28 PM CT), and a poster of prespecified pooled analyses from the Phase 3 T2D program (Nov 8, 2:30–3:30 PM CT).
The company said these data differentiate sotagliflozin from other SGLT inhibitors and myosin inhibitors and will be followed by additional presentations at CVCT 2025 in December.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will report third quarter 2025 financial results on Thursday, November 6, 2025, before market open. Management will host a conference call and live webcast on that day at 8:30 a.m. ET (7:30 a.m. CT) to discuss results and provide a business update.
Investors can access the live webcast via the company Events page at https://investors.lexpharma.com/. Participants who wish to ask questions must register to receive dial-in numbers and a unique PIN. An archived webcast will be posted on the Lexicon website after the call.
Lexicon Pharmaceuticals (Nasdaq: LXRX) presented additional Phase 2 pilavapadin data for diabetic peripheral neuropathic pain (DPNP) on Oct 14, 2025. Analyses support advancing a 10 mg once-daily dose into Phase 3 and a U.S. FDA end-of-Phase 2 meeting request has been accepted.
The pooled post-hoc analysis covered >600 patients from RELIEF-DPN 1 and PROGRESS, reported a 2-point average daily pain score (ADPS) reduction at 12 weeks for 10 mg, showed a linear exposure-response relationship, found an acceptable safety and tolerability profile, and noted lower adherence and increased tolerability symptoms in the PROGRESS 20 mg arm. A slide deck is available on the company events page.
Lexicon Pharmaceuticals (NASDAQ: LXRX) convened a stakeholder roundtable on Oct 8, 2025 at BIO headquarters to discuss public policy gaps for people with chronic pain and options to expand the Alternatives to PAIN Act to include chronic pain.
Participants included clinicians, patient advocates, and individuals affected by pain. The meeting cited U.S. Pain Foundation estimates of ~50 million Americans with chronic pain and costs of up to $635 million annually. Lexicon said it will publish a White Paper summarizing the roundtable outcomes and advocated for broader Medicare Part D access to non-opioid therapies beyond acute and post‑surgical pain.
FAQ
What is the current stock price of Lexicon Pharmaceuticals (LXRX)?
What is the market cap of Lexicon Pharmaceuticals (LXRX)?
